CN1957959A - Medication for treating chronic pharyngitis, sensitivity, and preparation method - Google Patents
Medication for treating chronic pharyngitis, sensitivity, and preparation method Download PDFInfo
- Publication number
- CN1957959A CN1957959A CN 200510110009 CN200510110009A CN1957959A CN 1957959 A CN1957959 A CN 1957959A CN 200510110009 CN200510110009 CN 200510110009 CN 200510110009 A CN200510110009 A CN 200510110009A CN 1957959 A CN1957959 A CN 1957959A
- Authority
- CN
- China
- Prior art keywords
- eucalypti robustae
- fructus
- volatile oil
- fructus eucalypti
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
A medicine for treating chronic pharyngitis and anaphylaxis is prepared from a natural plant Yikouzhong. Its preparing process is also disclosed.
Description
Technical field
The present invention relates to a kind of treatment chronic pharyngitis, antianaphylactic medicine; The invention still further relates to the preparation method of this treatment chronic pharyngitis, antianaphylactic medicine.
Background technology
In the prior art there be much the Chinese medicine of treatment chronic pharyngitis, for example, Chinese patent application CN1135908A is in disclosed a kind of medicine-food two-purpose Chinese patent medicine Yinyanling acute, the chronic pharyngitis disease for the treatment of on November 20th, 1996.This medicine is by Fructus Momordicae, Fructus Canarii, Fructus Phyllanthi, Flos Carthami, Flos Chrysanthemi, Herba Portulacae, Herba Menthae, Mesocarpium citrulli, Semen pruni armeniacae, Radix Platycodonis, Fructus Hippophae, Fructus Crataegi, Folium Perillae, Radix Platycodonis, Radix Glycyrrhizae, Fructus Mume, Bulbus Lilii, Fructus Schisandrae Chinensis, Semen Nelumbinis, Semen Ziziphi Spinosae, Pericarpium Citri Reticulatae, Arillus Longan, Fructus Lycii, Fructus Mori, Semen Coicis, fragrant minor official, Semen Sesami Nigrum, Semen Cassiae, Rhizoma Dioscoreae, Semen Raphani, Fructus Jujubae, the multiple medicine-food two-purpose Chinese herbal medicine of crystal sugar combine, and can make multiple dosage forms such as tablet, pill, electuary, medicinal tea, unguentum, powder, capsule, cake agent.Chinese patent application CN1142377A was on 02 12nd, 1997 disclosed a kind of Chinese medicine compositions for the treatment of chronic pharyngitis, contained component and percentage by weight thereof consist of: Radix Asparagi 10～25, Radix Ophiopogonis 5～15, Radix Glehniae 5～15, Rhizoma Polygonati Odorati 5～15, Flos Lonicerae 5～15, Radix Glycyrrhizae 1～10, Flos Chrysanthemi Indici 5～15, Pericarpium Citri Reticulatae 1～10, Semen Sterculiae Lychnophorae 10～25; Chinese patent application CN1348808A relates to a kind of Chinese medicine preparation for the treatment of chronic pharyngitis on 05 15th, 2002 disclosed a kind of medicaments for the treatment of chronic pharyngitis.Mainly be for the medicament effective percentage that solves existing treatment chronic pharyngitis is low, easily problem such as recurrence is developed; Comprise the Radix Rehmanniae, Radix Scrophulariae, Radix Ophiopogonis, Radix Glycyrrhizae, Bulbus Fritillariae Uninbracteatae, white peony root, Herba Menthae, Herba Scutellariae Barbatae, Cortex Moutan, Poria, Periostracum Cicadae, wooden butterfly battlements, Cortex Magnoliae Officinalis, Herba Dendrobii in the raw material.Chinese patent application CN1602946A was on 04 06th, 2005 disclosed a kind of buccal tablet for the treatment of acute/chronic pharyngitis and oral inflammation, comprise the active component and/or the pharmaceutically acceptable additives that make by following raw materials according: Radix Ophiopogonis the 30-80 weight portion, Radix Scrophulariae 30-80 weight portion, Pericarpium Trichosanthis 30-80 weight portion, terminalia flesh 30-80 weight portion, Fructus Canarii 15-35 weight portion, Membrana Follicularis ovi 3-8 weight portion, Radix Platycodonis 60-160 weight portion, Bulbus Fritillariae Thunbergii 60-160 weight portion, Poria 30-80 weight portion, Radix Glycyrrhizae 60-160 weight portion, cane sugar powder 250-350 weight portion, white dextrin 380-460 weight portion, magnesium stearate 5-15 weight portion, above raw material are made 1000 of buccal tablets altogether.
The compound recipe that all adopts in the above-mentioned open source literature does not see that as yet single medicinal material or a plant variety are open as the document of treatment chronic pharyngitis medicine.
Fructus Eucalypti Robustae is Eucalyptus globules Fruits again, it is the medical herbs of usefulness among the people simply, its effect for bring down a fever, antibiotic, antiviral, antiinflammatory etc., be mainly used in treatment flu, cholecystitis (Chinese patent CN93111684.8), gastric and duodenal ulcers (Chinese patent CN02138751.6), rheumatic arthritis (Chinese patent CN03125238.9) etc.The sixties in last century, the rural area lacked medicine, and many hospitals, commune hospital, middle and primary schools all once used Fructus Eucalypti Robustae orally taken for curing influenza to boil water and epidemic encephalitis, had played effect preferably.Still there is not the report that Fructus Eucalypti Robustae is used for the treatment of chronic pharyngitis and has anti-allergic effects in the document.
Summary of the invention
At the above-mentioned deficiency of prior art, the technical problem to be solved in the present invention is to propose suitable treatment chronic pharyngitis, the antianaphylactic single medicinal material of a kind of and existing compound effect.
The present invention solves its technical problem and the technical scheme that adopts is based on the inventor and has found that Fructus Eucalypti Robustae has the medical function of treatment chronic pharyngitis and has good anti-allergic effects.Treatment chronic pharyngitis, the Claritin that the present invention proposes is to be the medicament that feedstock production forms by Fructus Eucalypti Robustae, and this medicament is a said dosage form on any pharmaceutics.
As the preferred technical solution of the present invention, above-mentioned pharmacy optimization is decoction or volatile oil.
The above-mentioned raw materials medicine is made medicine production method of the present invention is: take by weighing the Fructus Eucalypti Robustae crude drug, add 10 times of water gagings and soak, boiled 1 hour, filter; In medicinal residues, add 8 times of water gagings, fry in shallow oil 40min again, filter; Merge filtrate twice, concentrate, make decoction.Above-mentioned decoction is concentrated into half thick shape after drying, makes extractum.
The present invention has observed the effect to the chronic pharyngitis pharmacodynamic index of Fructus Eucalypti Robustae decocting liquid and volatile oil according to the guideline of the pharmacodynamic study of chronic pharyngitis.The result proves that the Fructus Eucalypti Robustae tool suppresses the effect of rat granulation hyperplasia, but effect is strong not as positive control drug glucocorticoid cortisone, because the toxic and side effects of cortisone prolonged application, the effect of Fructus Eucalypti Robustae is very important.After the application carrageenin causes rat paw edema, observe the effect that Fructus Eucalypti Robustae has significant inhibition pedal swelling, although effect slightly is inferior to the positive control drug aspirin, side effect is light far beyond aspirin.The effect of expectorant test proof Fructus Eucalypti Robustae is very strong, outclass positive control drug ammonium chloride.Rat passive cutaneous anaphylaxis test method of the same race (PCA) proves that the rat skin permeability that Fructus Eucalypti Robustae can significantly suppress after antiserum inoculation and antigen attack obviously increases, and illustrates that it has good anti-allergic effects.Acute toxicity test shows and can't measure LD by medicine
50Acute toxicity test method according to medicine, adopt the maximum tolerance determination method, the maximum tolerated dose that calculates Fructus Eucalypti Robustae decocting liquid is equivalent to 800 times of the clinical consumption of people, volatile oil is equivalent to 1000 times of the clinical consumption of people, the result shows that Fructus Eucalypti Robustae decocting liquid extract and volatile oil do not have overt toxicity, and clinical safety is reliable.When dosage reaches 1000g/kg, still can not measure the toxic action of Fructus Eucalypti Robustae decocting liquid and volatile oil, illustrate that its maximum toleration surpasses 100 times of experimental drugs, points out this medicine basic free of toxic effects.Above result has proved that Fructus Eucalypti Robustae is the treatment chronic pharyngitis that toxicity is little simply, comprehensive function is stronger, antianaphylactic potential newtype drug.
Description of drawings
Fig. 1 is Fructus Eucalypti Robustae decocting liquid and the volatile oil impact effect figure to the rat granulation hyperplasia.
Fig. 2 is the impact effect figure of rat paw inflammation due to Fructus Eucalypti Robustae decocting liquid and the volatile oil on Carrageenan.
Fig. 3 is Fructus Eucalypti Robustae decocting liquid and the volatile oil impact effect figure to the phenol red excretion amount of mice trachea section.
Fig. 4 is Fructus Eucalypti Robustae decocting liquid and the volatile oil inhibitory action design sketch to P of Rats CA.
The specific embodiment
Below in conjunction with embodiment and accompanying drawing the present invention is further described.
Embodiment 1 (extraction of Fructus Eucalypti Robustae decocting liquid)
Take by weighing Fructus Eucalypti Robustae crude drug 400g, add 4000ml water logging bubble 30min, boil 1 hour (picking up counting after the boiling), filter filtrate for later use; Add 3200ml water again and fry in shallow oil 40min again in medicinal residues, filter, twice filtrate merges, and concentrates.Other gets crude drug 450g, adds 4500ml water logging bubble 30min, boils 1 hour (picking up counting after the boiling), filters filtrate for later use; Add 3600ml water again and fry in shallow oil 40min again in medicinal residues, filter, twice filtrate merges, and concentrates.Put into the aluminum pot heating filtrate merging with four times then and be concentrated into certain denseness, change over to again in the little stainless steel disc, place microwave oven interior (50 ℃) to be concentrated into half thick shape.Batch pan was put into vacuum drying oven dry (70 ℃) 3.5 hours, at last clean cream 167.6g, yield is 19.7%.
Embodiment 2 (extraction of Fructus Eucalypti Robustae volatile oil)
Divide 4 input volatile oil extractors to extract 900g Fructus Eucalypti Robustae crude drug, merge four times oilyly at last, be total to 48ml, oil yield 5.33%.
Pharmacodynamics test
Among the people, Fructus Eucalypti Robustae people's dosage is generally the 3g/60kg body weight, be 50mg/kg, 6 times of behaving of the dosage of rat, i.e. 300mg/kg, 8 times of behaving of the dosage of mice, being 400mg/kg, is the middle dosage of laboratory animal in this experiment with this dosage setting, on this basis, increase by 3 times as heavy dose of, reduce 3 times as low dose of.According to Fructus Eucalypti Robustae decocting liquid and volatile oil yield, be converted into the dosage of experiment.
1. antiinflammatory test
Form experiment 1.1 suppress granuloma
Rat cotton balls implantation: choose body weight and be 80 of Wistar rats about 200g, male and female half and half, the anesthesia of 2% pentobarbital sodium, Mao Bingyong 70% alcohol disinfecting is shaved at the back, do a kerf at waist, upwards do a subcutaneous with the passivity tweezers by incision, sterilized cotton ball is implanted the scapula subcutaneous location (left and right sides forelimb oxter) of both sides.Selected cotton balls is the standard cotton balls of 20mg, postoperative began administration the same day, the Fructus Eucalypti Robustae group is irritated stomach and is given Fructus Eucalypti Robustae decocting liquid, Fructus Eucalypti Robustae volatilization line of oils is irritated stomach and is given Fructus Eucalypti Robustae volatile oil, and model group gives the 0.5%CMC of 2ml, cortisone group intramuscular administration, continuous 9 days, rat is put to death in dislocation in the tenth day, takes out cotton balls, peels off the granuloma tissue.70 ℃ were dried by the fire 4 hours, weighed, and deducted cotton balls and heavily were granuloma weight.
Be divided into 8 groups at random, every group of male and female half and half, 1. matched group; 2. cortisone group (25mg/kg/day); 3. Fructus Eucalypti Robustae small dose group (20mg/kg/day); 4. dosage group (60mg/kg/day) in the Fructus Eucalypti Robustae; 5. the Fructus Eucalypti Robustae heavy dose is organized (180mg/kg/day); 6. Fructus Eucalypti Robustae volatile oil small dose group (5mg/kg/day); 7. dosage group (15mg/kg/day) in the Fructus Eucalypti Robustae volatile oil; 8. Fructus Eucalypti Robustae volatile oil heavy dose is organized (45mg/kg/day).The same model group of volume (2ml) of stomach that said medicine is irritated.
1.2 the rat paw carrageenin causes scorching test
Choose body weight and be 80 of Wistar rats about 200g, be divided into 8 groups at random, every group of male and female half and half, 1. matched group (distilled water 2ml); 2. aspirin group (300mg/kg/day); 3. Fructus Eucalypti Robustae small dose group (20mg/kg/day); 4. dosage group (60mg/kg/day) in the Fructus Eucalypti Robustae; 5. the Fructus Eucalypti Robustae heavy dose is organized (180mg/kg/day); 6. Fructus Eucalypti Robustae volatile oil small dose group (5mg/kg/day); 7. dosage group (15mg/kg/day) in the Fructus Eucalypti Robustae volatile oil; 8. Fructus Eucalypti Robustae volatile oil heavy dose is organized (45mg/kg/day).Every day, gastric infusion was 1 time, and continuous 9 days, behind the last administration 30min, subcutaneous injection 0.8% carrageenin 0.1ml caused inflammation to rat left hind foot pad portion.With YLS-7A foot sole of the foot volumetric measurement instrument (equipment station, the Academy of Medical Sciences, Shandong) measures respectively cause scorching preceding and cause the volume of 1h, 2h after the inflammation, 3h, 5h rat paw edema, its difference is swelling degree (ml), respectively organize the difference (annotating: make a labelling with marking pen at sufficient sole of the foot place before measuring the rat paw volume, all be as the criterion later at every turn) of swelling degree with this labelling.
2. eliminate the phlegm (with phenol red respiratory tract excretion laboratory observation Fructus Eucalypti Robustae decocting liquid and volatile oil phlegm-dispelling functions) to mice
Get 120 (18-22g) male and female half and half of Kunming mouse, be divided into 8 groups at random, 15 every group (every group ♀ 8, ♂ 7 or ♀ 7, ♂ 8) numbering is weighed and record: 1) model group; 2) ammonium chloride group (1000mg/kg); 3) Fructus Eucalypti Robustae small dose group (26.7mg/kg); 4) dosage group (80mg/kg) in the Fructus Eucalypti Robustae; 5) the heavy dose of group of Fructus Eucalypti Robustae (240mg/kg); 6) Fructus Eucalypti Robustae volatile oil small dose group (6.67mg/kg); 7) dosage group (20mg/kg) in the Fructus Eucalypti Robustae volatile oil; 8) the heavy dose of group of Fructus Eucalypti Robustae volatile oil (60mg/kg).Observe phlegm-dispelling functions with the phenol red drainage method of mice trachea section.Fasting be can't help water 12 hours before the experiment, and administration is after 30 minutes, calculated with 5mg/10g body weight (2.5% solution 0.2ml/10g) respectively, and intraperitoneal injects phenol red liquid, injected behind the phenol red liquid and to put to death animal in 30 minutes.Cut this section trachea of thyroid cartilage, put into the test tube that fills the 2ml normal saline, concussion back standing over night down to the trachea crotch.Take out invisible spectro trachea, remove float in the liquid, obtain supernatant 1.5ml, add 1mol/l sodium hydroxide 0.05ml again, use Spectra max with centrifuging
@190 microplate reader (U.S. Molecular Devices company) are measured the OD value at 546nm wavelength place.Make a standard curve with the phenol red liquid of concentration known.According to the phenol red content of curve calculation (g/ml).
Attached: the preparation before the experiment
● 2.5% phenol red solution: accurately take by weighing phenol red 2.5 grams,, add normal saline, shake up promptly to 100ml with 1mol/L NaOH solution 2.5ml dissolving.
● the preparation of the phenol red liquid of standard: the phenol red liquid of getting 6mg/ml is diluted to 1000 μ g/ml with normal saline, be diluted to every milliliter of standard pipe that contains phenol red 1 μ g, 2 μ g, 3 μ g, 4 μ g, 5 μ g, 6 μ g, 7 μ g, 8 μ g, 9 μ g, 10 μ g then successively, every pipe 3ml every pipe in addition adds 2 of 10% sodium hydroxide solutions, seals standby.
● experiment equipment: centrifuge, Spectra max
@190 microplate reader, mouse stomach device, operating scissors, tweezers, test tube, syringe etc.
3. allergic experiment---rat passive cutaneous anaphylaxis test method of the same race (PCA)
3.1 sero-fast preparation:
Get 70 of Wistar rats about 150g, male and female half and half, other gets 6 of 200g left and right sides male Wistar rats, is divided into 7 groups (every group comprises each 5 of male and female) immediately
1. matched group; 2. Fructus Eucalypti Robustae small dose group (20mg/kg/d); 3. dosage group (60mg/kg/day) in the Fructus Eucalypti Robustae; 4. the Fructus Eucalypti Robustae heavy dose is organized (180mg/kg/day); 5. Fructus Eucalypti Robustae volatile oil small dose group (5mg/kg/day); 6. dosage group (15mg/kg/day) in the Fructus Eucalypti Robustae volatile oil; 7. Fructus Eucalypti Robustae volatile oil heavy dose is organized (45mg/kg/day).
Radix Trichosanthis is made into the antigen suspension of 2.5mg/ml with 6% gel aluminum hydroxide, each sole injection 0.1ml, every Mus is injected 0.4ml (being Radix Trichosanthis 1mg) altogether, injected back 12 days, the ventral aorta blood sampling was left standstill more than 2 hours, and 3500rpm is centrifugal, and 15min gets antiserum, dilution ratio is 1: 10, puts below-4 ℃ standby.
3.2 antiserum inoculation and antigen are attacked:
Other gets the 150g normal Wistar rats, pentobarbital sodium anesthesia lower back portion is shaved hair, each 2 above-mentioned antiserum 0.1ml of subcutaneous injection of dorsal line both sides, carrying out antigen after 48 hours attacks, be intravenous injection Radix Trichosanthis 10mg/kg (being made into 1mg/ml) with 1% azovan blue, behind the 30min, the sacrificed by decapitation animal, the upset skin of back, measure and the blue reaction of record spot diameter size, or cut locus coeruleus skin, shred, place the band plug centrifuge tube that contains 6ml acetone-normal saline (7: 3), fully shake up, soak 48h, centrifugal, get supernatant, measure optical density (OD) at 610nm wavelength place.30min gastric infusion before carrying out the antigen attack.Calculate the inhibition percentage rate of administration group to the PCA reaction, its computing formula is as follows:
Suppress percentage rate=(matched group locus coeruleus optical density-medication group locus coeruleus optical density) ÷ matched group locus coeruleus optical density * 100%
Attention: 1. sero-fast dilution ratio is 1: 16-1: 40, and strictness is said and should be carried out suitable dilution according to sero-fast titre.
Antigen attack to the time of sacrificed by decapitation animal must be accurate, otherwise will influence result's correctness.
4. acute toxicity testing
Preliminary experiment shows the acute toxicity that can not measure Fructus Eucalypti Robustae decocting liquid and volatile oil, transforms the maximum tolerated dose experiment into.
4.1 experiment is prepared:
● animal: 40 of Kunming mouses, 18 ~ 22g, male and female half and half.The needle and syringe head, wire mesh cage.
● medicine: Fructus Eucalypti Robustae decocting liquid and extractive of volatile oil, picric acid solution, sodium carboxymethyl cellulose (CMC-Na), Tween 80.
Compound method:
1) 0.5g CMC-Na is dissolved in 100ml water, makes 0.5%CMC-Na.
2) 4g decocting liquid extract is suspended in 0.5%CMC-Na (20ml), makes 200mg/ml.(dosage is 0.2ml/10g, and concentration is 200mg/ml, and dosage is 8g/kg)
3) volatile oil: Tween 80: water=1: 1: 8, be made into emulsifying agent, be diluted to 62mg/ml.(dosage is 0.2ml/10g, and concentration is 62mg/ml, and dosage is 2.5g/kg)
4.2 experimental technique:
● get 40 of 18 ~ 22g Kunming mouses (male and female half and half), fasting be can't help water 12 hours.
● in the 0.5%CMC-Na suspension of orally give 200mg/ml Fructus Eucalypti Robustae decocting liquid extract next day, dosage is 0.2ml/10g, one day twice, 4 hours (fasting) at interval, accumulated dose is 8g/kg.Totally 20 animals (male and female half and half).
● observe animal behavior activity, state, death condition etc. after the administration in seven days, noted down every day.
Feeding environment: Shanghai Univ. of Traditional Chinese Medicine's cleaning level animal feeding room, temperature is 25 ℃, relative humidity 30% ~ 70%.Raise and drinking water, sub-cage rearing, every cage are 5 of same sex animals.
● give the decocting liquid extract on the same day, other gets 20 (male and female half and half) and gives Fructus Eucalypti Robustae volatile oil 0.2ml/10g, one day twice, at interval 4 hours (fasting), accumulated dose is 2.5g/kg.Observed content is with decocting liquid group after the administration.
5. statistical procedures
All experimental result is all with mean ± standard deviation (X ± SD) expression.Check the relatively significant difference of data between two groups with Student-t, P＜0.05 expression has statistical significance.
Three, experimental result
1. Fructus Eucalypti Robustae is to the inhibitory action of rat granulation hyperplasia
As seen using the granulomatous weight that the cotton balls implantation causes according to the result of table 1 and Fig. 1 is 173.2 ± 5.284mg, after using cortisone, granulomatous weight obviously alleviates, and compares with model group, its suppression ratio is 77.4%, and difference is (P＜0.001) quite significantly.The granulomatous effect that the water extract of Fructus Eucalypti Robustae and volatile oil all have inhibition to cause by the cotton balls implantation, the action intensity of the two is equal substantially, should have dose-effect relationship.But the effect of Fructus Eucalypti Robustae and cortisone relatively obviously are weaker than cortisone, have the effect that suppresses granulation hyperplasia although Fructus Eucalypti Robustae is described, effect can not show a candle to glucocorticoid.
Table 1. Fructus Eucalypti Robustae decocting liquid and volatile oil are to the influence (n=10) of rat granulation hyperplasia
| Group | Dosage (mg/kg) | Granuloma weight (mg) | Suppression ratio (%) |
| Model group | - | 173.2±5.28 | - |
| The cortisone group | 25 | 39.1±3.03 *** | 77.4 |
| The Fructus Eucalypti Robustae small dose group | 20 | 157.9±3.54 * | 8.8 |
| Dosage group in the Fructus Eucalypti Robustae | 60 | 150.9±2.86 * | 12.9 |
| The heavy dose of group of Fructus Eucalypti Robustae | 180 | 129.9±2.54 ** | 25.0 |
| Fructus Eucalypti Robustae volatile oil | 5 | 162.4±4.95 * | 6.2 |
| Dosage group in the Fructus Eucalypti Robustae volatile oil | 15 | 154.2±3.37 * | 11.0 |
| The heavy dose of group of Fructus Eucalypti Robustae volatile oil | 45 | 131.6±2.99 ** | 24.0 |
Compare with model group:
*P＜0.05,
*P＜0.01,
* *P＜0.001
2. the effect of rat paw inflammation due to the Fructus Eucalypti Robustae on Carrageenan
As seen use carrageenin according to the result of table 2 and Fig. 2 and cause the rat paw inflammatory reaction, cause the pedal swelling after the inflammation, increase, during to 3 hours, reach summit, subsequently, descend gradually along with the prolongation of time.Use the anti-inflammatory agent aspirin and can suppress rat paw edema due to the carrageenin significantly, after causing inflammation the 1st hour, compare with model group, there was no significant difference, but from the 2nd hour until experiment end (5 hours), the degree of pedal swelling, the decline of time dependence ground, compare with model group, have notable difference.After using the water extract and volatile oil of Fructus Eucalypti Robustae, the situation that alleviates of pedal swelling is similar to aspirin, and effect is weaker than aspirin slightly, although there is dose-effect relationship, but not remarkable.
The influence (n=10) of rat paw inflammation due to table 2. Fructus Eucalypti Robustae decocting liquid and the volatile oil on Carrageenan
| Group | Dosage (mg/k g) | Cause scorching back different time swelling degree of the paw (ml) | |||
| 1h | 2h | 3h | 5h | ||
| Model group | -- | 0.2656±0.009 | 0.3956±0.027 | 0.5638±0.036 | 0.3867±0.025 |
| The aspirin group | 300 | 0.2663±0.009 | 0.2787±0.010 ** | 0.2577±0.007 ** | 0.1204±0.007 ** |
| The Fructus Eucalypti Robustae small dose group | 20 | 0.2657±0.006 | 0.3641±0.012 * | 0.3350±0.016 * | 0.2196±0.017 * |
| Dosage group in the Fructus Eucalypti Robustae | 60 | 0.2580±0.010 | 0.3285±0.015 * | 0.3204±0.009 * | 0.1991±0.018 * |
| The heavy dose of group of Fructus Eucalypti Robustae | 180 | 0.2595±0.008 | 0.3357±0.012 * | 0.3261±0.012 * | 0.1783±0.007 ** |
| Fructus Eucalypti Robustae volatile oil | 5 | 0.2644±0.008 | 0.3753±0.011 | 0.3392±0.013 * | 0.2176±0.010 * |
| Dosage group in the Fructus Eucalypti Robustae volatile oil | 15 | 0.2613±0.007 | 0.3289±0.013 * | 0.3320±0.016 * | 0.2060±0.010 * |
| The heavy dose of group of Fructus Eucalypti Robustae volatile oil | 45 | 0.2643±0.011 | 0.3380±0.014 * | 0.3186±0.012 * | 0.1971±0.018 * |
Compare with model group:
*P＜0.05,
*P＜0.01
3. Fructus Eucalypti Robustae is to the influence of the phenol red excretion amount of mice trachea section
The phenol red content of the presentation of results model group mice of table 3 and Fig. 3 is 2.320 ± 0.546 μ g/ml, and behind the application ammonium chloride, the phenol red excretion amount of mice trachea section increases, and compares with model group, has significant difference (P＜0.01).After using the water extract and volatile oil of Fructus Eucalypti Robustae, the phenol red excretion amount of mice trachea section obviously increases, and presents dose-dependent effects, when heavy dose, no matter is water extract or volatile oil, and its effect obviously is better than ammonium chloride.
Table 3. Fructus Eucalypti Robustae decocting liquid and volatile oil are to the influence (n=15) of the phenol red excretion amount of mice trachea section
| Group | Dosage (mg/kg) | Phenol red content (μ g/ml) |
| Model group | -- | 2.320±0.546 |
| The ammonium chloride group | 1000 | 4.113±1.083 * |
| The Fructus Eucalypti Robustae small dose group | 26.7 | 2.258±0.312 |
| Dosage group in the | 80 | 4.118±1.235 * |
| The heavy dose of group of Fructus Eucalypti Robustae | 240 | 5.502±1.632 * |
| Fructus Eucalypti Robustae volatile oil small dose group | 6.67 | 2.135±0.245 |
| Dosage group in the Fructus Eucalypti Robustae volatile oil | 20 | 4.214±0.931 * |
| The heavy dose of group of Fructus Eucalypti Robustae volatile oil | 60 | 5.690±0.836 * |
Compare with model group:
*P＜0.01
4. Fructus Eucalypti Robustae is to the inhibitory action of rat passive cutaneous anaphylaxis test method of the same race (PCA)
The rat skin permeability of the presentation of results of table 4 and Fig. 4 after antiserum inoculation and antigen attack obviously increases, the optical density of being surveyed is 0.406 ± 0.062 (0D), after using the water extract and volatile oil of Fructus Eucalypti Robustae, the optical density of being surveyed, be dose dependent and descend, the effect of water extract slightly is better than volatile oil.Water extract compares with model group heavy dose of at middle dosage and heavy dose, volatile oil, has significant difference (P＜0.05).
Table 4. Fructus Eucalypti Robustae decocting liquid and volatile oil are to the inhibitory action (n=10) of P of Rats CA
| Group | Dosage (mg/kg) | The OD value (λ=610nm) |
| Model group | -- | 0.406±0.062 |
| The Fructus Eucalypti Robustae small dose group | 20 | 0.392±0.055 |
| Dosage group in the Fructus Eucalypti Robustae | 60 | 0.328±0.048 * |
| The heavy dose of group of Fructus Eucalypti Robustae | 180 | 0.267±0.041 * |
| Fructus Eucalypti Robustae volatile oil | 5 | 0.403±0.051 |
| Dosage group in the Fructus Eucalypti Robustae volatile oil | 15 | 0.384±0.046 |
| The heavy dose of group of Fructus Eucalypti Robustae volatile oil | 45 | 0.291±0.050 * |
Compare with model group:
*P＜0.05
Table 5. Fructus Eucalypti Robustae decocting liquid is to the observation (n=10) of male rat acute toxicity effect
| Numbering | Observing time | Spontaneous activity | The abnormal muscle activity | Reaction | Pupil | Secretion | Stool | The colour of skin | Eye | Breathe | Other | |||||||||||
| Twitch | Paralysis | Abnormal gait | Irritated | Indifferently | Enlarge | Dwindle | Sialorrhea | Shed tears | Just rare | Constipation | Color and luster is unusual | Pale | Cyanosis | Congested | Exophthalmos | Blepharoptosis | Excited | Suppress | ||||
| 1 | 5 | Normally | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Do not have |
| 2 | 5 | Normally | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Do not have |
| 3 | 5 | Normally | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Do not have |
| 4 | 5 | Normally | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Do not have |
| 5 | 5 | Normally | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Do not have |
| 6 | 5 | Normally | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Do not have |
| 7 | 5 | Normally | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Do not have |
| 8 | 5 | Normally | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Do not have |
| 9 | 5 | Normally | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Do not have |
| 10 | 5 | Normally | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Do not have |
5. the preceding liquid of Fructus Eucalypti Robustae water is to the toxic influence of rat acute
In 7 days, do not find that undue toxicity's symptom appears in mice, physiological features such as its behavior, activity, breathing, drainage are normal, and diet and body weight change are all in normal range.The result of table 5, table 6, table 7, table 8 shows that Fructus Eucalypti Robustae decocting liquid and volatile oil do not influence listed a series of observation index, all is negative findingses.
The oral maximum tolerated dose of mice of Fructus Eucalypti Robustae decocting liquid extract is 8g/kg, and the maximum tolerated dose on the one that calculates Fructus Eucalypti Robustae decocting liquid is equivalent to 800 times of the clinical consumption of people.
The oral maximum tolerated dose of the mice of Fructus Eucalypti Robustae volatile oil is 2.5g/kg, and the maximum tolerated dose on the one that calculates Fructus Eucalypti Robustae volatile oil is equivalent to 1000 times of the clinical consumption of people.
Table 6. Fructus Eucalypti Robustae decocting liquid is to the observation (n=10) of female rats acute toxicity effect
| Numbering | Observing time | Spontaneous activity | The abnormal muscle activity | Reaction | Pupil | Secretion | Stool | The colour of skin | Eye | Breathe | Other | |||||||||||
| Twitch | Paralysis | Abnormal gait | Irritated | Indifferently | Enlarge | Dwindle | Sialorrhea | Shed tears | Just rare | Constipation | Color and luster is unusual | Pale | Cyanosis | Congested | Exophthalmos | Blepharoptosis | Excited | Suppress | ||||
| 1 | 5 | Normally | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Do not have |
| 2 | 5 | Normally | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Do not have |
| 3 | 5 | Normally | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Do not have |
| 4 | 5 | Normally | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Do not have |
| 5 | 5 | Normally | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Do not have |
| 6 | 5 | Normally | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Do not have |
| 7 | 5 | Normally | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Do not have |
| 8 | 5 | Normally | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Do not have |
| 9 | 5 | Normally | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Do not have |
| 10 | 5 | Normally | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Do not have |
Table 7. Fructus Eucalypti Robustae volatile oil is to the observation (n=10) of male rat acute toxicity effect
| Numbering | Observing time | Spontaneous activity | The abnormal muscle activity | Reaction | Pupil | Secretion | Stool | The colour of skin | Eye | Breathe | Other | |||||||||||
| Twitch | Paralysis | Abnormal gait | Irritated | Indifferently | Enlarge | Dwindle | Sialorrhea | Shed tears | Just rare | Constipation | Color and luster is unusual | Pale | Cyanosis | Congested | Exophthalmos | Blepharoptosis | Excited | Suppress | ||||
| 1 | 5 | Normally | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Do not have |
| 2 | 5 | Normally | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Do not have |
| 3 | 5 | Normally | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Do not have |
| 4 | 5 | Normally | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Do not have |
| 5 | 5 | Normally | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Do not have |
| 6 | 5 | Normally | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Do not have |
| 7 | 5 | Normally | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Do not have |
| 8 | 5 | Normally | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Do not have |
| 9 | 5 | Normally | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Do not have |
| 10 | 5 | Normally | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Do not have |
Table 8. Fructus Eucalypti Robustae volatile oil is to the observation (n=10) of female rats acute toxicity effect
| Numbering | Observing time | Spontaneous activity | The abnormal muscle activity | Reaction | Pupil | Secretion | Stool | The colour of skin | Eye | Breathe | Other | |||||||||||
| Twitch | Paralysis | Abnormal gait | Irritated | Indifferently | Enlarge | Dwindle | Sialorrhea | Shed tears | Just rare | Constipation | Color and luster is unusual | Pale | Cyanosis | Congested | Exophthalmos | Blepharoptosis | Excited | Suppress | ||||
| 1 | 5 | Normally | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Do not have |
| 2 | 5 | Normally | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Do not have |
| 3 | 5 | Normally | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Do not have |
| 4 | 5 | Normally | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Do not have |
| 5 | 5 | Normally | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Do not have |
| 6 | 5 | Normally | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Do not have |
| 7 | 5 | Normally | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Do not have |
| 8 | 5 | Normally | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Do not have |
| 9 | 5 | Normally | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Do not have |
| 10 | 5 | Normally | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | Do not have |
Claims (6)
1, a kind of treatment chronic pharyngitis, antianaphylactic medicine is characterized in that it is is the medicament that feedstock production forms by Fructus Eucalypti Robustae.
2, treatment chronic pharyngitis according to claim 1, antianaphylactic medicine is characterized in that described medicament is a said dosage form on any pharmaceutics.
3, treatment chronic pharyngitis according to claim 2, antianaphylactic medicine is characterized in that described medicament is a decoction.
4, treatment chronic pharyngitis according to claim 2, antianaphylactic medicine is characterized in that described medicament is a volatile oil.
5, the preparation method of the described treatment chronic pharyngitis of claim 3, antianaphylactic medicine is characterized in that taking by weighing the Fructus Eucalypti Robustae crude drug, adds 10 times of water gagings and soaks, and boils 1 hour, filters; In medicinal residues, add 8 times of water gagings, fry in shallow oil 40min again, filter; Merge filtrate twice, concentrate, make decoction.
6, the preparation method of the described treatment chronic pharyngitis of claim 4, antianaphylactic medicine is characterized in that the Fructus Eucalypti Robustae crude drug is dropped into volatile oil extractor to be extracted, and makes volatile oil.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510110009 CN1957959A (en) | 2005-11-03 | 2005-11-03 | Medication for treating chronic pharyngitis, sensitivity, and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200510110009 CN1957959A (en) | 2005-11-03 | 2005-11-03 | Medication for treating chronic pharyngitis, sensitivity, and preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1957959A true CN1957959A (en) | 2007-05-09 |
Family
ID=38069912
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200510110009 Pending CN1957959A (en) | 2005-11-03 | 2005-11-03 | Medication for treating chronic pharyngitis, sensitivity, and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1957959A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102138655A (en) * | 2011-04-02 | 2011-08-03 | 厦门嘉祺生物食品有限公司 | Novel formula for longan blood-supplementing ointment and preparation method thereof |
| CN117731737A (en) * | 2024-02-19 | 2024-03-22 | 云南红青夫生物科技股份有限公司 | Throat-clearing and-wetting lozenge |
-
2005
- 2005-11-03 CN CN 200510110009 patent/CN1957959A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102138655A (en) * | 2011-04-02 | 2011-08-03 | 厦门嘉祺生物食品有限公司 | Novel formula for longan blood-supplementing ointment and preparation method thereof |
| CN102138655B (en) * | 2011-04-02 | 2012-10-03 | 厦门嘉祺生物食品有限公司 | Novel formula for longan blood-supplementing ointment and preparation method thereof |
| CN117731737A (en) * | 2024-02-19 | 2024-03-22 | 云南红青夫生物科技股份有限公司 | Throat-clearing and-wetting lozenge |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100337651C (en) | Chinese medicine composition for preventing bird flu | |
| CN100342889C (en) | Chinese medicine for treating gout | |
| CN1857618A (en) | Chinese medicine preparation for reducing sugar | |
| CN1850153A (en) | Method for preparing Radix puerariae and cenlian decoction | |
| CN102552806B (en) | Fat-burning dredging particles and preparation method thereof | |
| CN103007111B (en) | Chinese medicinal preparation for treating diarrhea of rabbits and preparation method of Chinese medicinal preparation | |
| CN1943713A (en) | A Chinese traditional medicinal composition for treating diabetes and its preparation method | |
| CN1742775A (en) | Medicine composition for preventing and treating orthopedic diseases | |
| CN101032611A (en) | Antipruritic composite Chinese medicine and its preparing process | |
| CN1957959A (en) | Medication for treating chronic pharyngitis, sensitivity, and preparation method | |
| CN101732386B (en) | Medicinal composition for treating gout, preparation method thereof and purposes thereof | |
| CN1686424A (en) | Medicinal composition containing scutellaria and bupleurum and its preparation method | |
| CN105727089A (en) | Application of medicine composition containing folium artemisiae argyi to preparing medicine for treating irritable bowel syndrome | |
| CN106309736A (en) | Anti-fatigue traditional Chinese medicine composition as well as preparation method and application thereof | |
| CN102293883B (en) | Chinese medicinal composition for treating child acute upper respiratory tract infection, and preparation method and application thereof | |
| CN101884664B (en) | Medicinal composition for preventing and treating rheumatoid arthritis and preparation method thereof | |
| CN1795901B (en) | Medication for removing toxic heat, eliminating wetness and treating jaundice | |
| CN100434085C (en) | Process for removing toxic component from oleum fructus bruceae | |
| CN104436022A (en) | Hemsleya-macrosperma-containing traditional Chinese medicine composition for treating diabetes mellitus | |
| CN104474103A (en) | Natural plant hypoglycemic agent and preparation method thereof | |
| CN103751692B (en) | Special invigorating capsule of a kind of Testis et penis callorhini and preparation method thereof | |
| CN1126558C (en) | Medicine for treating kidney damage caused by immunological disease lupus erythematosus | |
| CN101045116A (en) | Traditional Chinese medicine for treating cholecystitis | |
| CN1245204C (en) | Medicine for curing acute pharyngitis and its preparing method | |
| CN1907315A (en) | Orthopaedics disease treating and preventing medicinal composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20070509 |